Adamas Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ADMS, Adamas Pharmaceuticals Inc, priceseries

Adamas Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
8.24
Close
8.22
High
8.25
Low
8.18
Previous Close
8.16
Daily Price Gain
0.06
YTD High
9.15
YTD High Date
Feb 1, 2021
YTD Low
4.02
YTD Low Date
Aug 16, 2021
YTD Price Change
3.74
YTD Gain
83.48%
52 Week High
9.15
52 Week High Date
Feb 1, 2021
52 Week Low
4.02
52 Week Low Date
Aug 16, 2021
52 Week Price Change
3.26
52 Week Gain
65.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 1. 2017
16.27
Jun 20. 2017
17.23
13 Trading Days
5.91%
Link
LONG
Oct 27. 2017
19.51
Nov 14. 2017
26.69
12 Trading Days
36.81%
Link
LONG
Nov 16. 2017
27.69
Dec 13. 2017
33.93
18 Trading Days
22.54%
Link
LONG
Apr 17. 2018
25.01
May 4. 2018
28.42
13 Trading Days
13.62%
Link
LONG
Jun 17. 2019
4.77
Jul 8. 2019
5.61
14 Trading Days
17.65%
Link
LONG
Sep 11. 2019
6.08
Sep 27. 2019
6.75
12 Trading Days
11.10%
Link
LONG
Nov 27. 2019
5.62
Dec 11. 2019
6.29
9 Trading Days
11.94%
Link
LONG
Jan 6. 2020
4.14
Jan 24. 2020
5.62
13 Trading Days
35.85%
Link
LONG
Aug 7. 2020
3.78
Aug 21. 2020
4.59
10 Trading Days
21.32%
Link
LONG
Aug 25. 2020
4.80
Sep 8. 2020
5.14
9 Trading Days
7.09%
Link
LONG
Nov 12. 2020
3.76
Dec 21. 2020
4.82
26 Trading Days
28.26%
Link
LONG
Jan 22. 2021
4.72
Feb 3. 2021
5.55
8 Trading Days
17.60%
Link
Company Information
Stock Symbol
ADMS
Exchange
NasdaqGM
Company URL
http://www.adamaspharma.com
Company Phone
510-450-3554
CEO
Gregory T. Went
Headquarters
California
Business Address
1900 POWELL ST., SUITE 750, EMERYVILLE, CA 94608
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001328143
About

Adamas Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in discovering chrono-synchronous therapies. It involves in the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Description

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's products under development include ADS-4101, a chrono-synchronous lacosamide therapy that has completed first Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading